These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2168152)

  • 1. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.
    Yasin SR; al-Nakib W; Tyrrell DA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):963-6. PubMed ID: 2168152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of rhinovirus resistant to an antiviral chalcone.
    Ahmad AL; Dowsett AB; Tyrrell DA
    Antiviral Res; 1987 Aug; 8(1):27-39. PubMed ID: 2825590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410.
    Ishitsuka H; Ninomiya YT; Ohsawa C; Fujiu M; Suhara Y
    Antimicrob Agents Chemother; 1982 Oct; 22(4):617-21. PubMed ID: 6295261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
    Ninomiya Y; Shimma N; Ishitsuka H
    Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
    Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
    Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Lenox-Smith I
    J Antimicrob Chemother; 1984 Oct; 14(4):403-9. PubMed ID: 6094423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.
    Al-Nakib W; Higgins PG; Barrow I; Tyrrell DA; Lenox-Smith I; Ishitsuka H
    J Antimicrob Chemother; 1987 Dec; 20(6):887-92. PubMed ID: 3326874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of drug resistance to new antirhinovirus agents.
    Ishitsuka H; Ninomiya Y; Suhara Y
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():11-8. PubMed ID: 3025150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.
    Ninomiya Y; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Antimicrob Agents Chemother; 1985 Apr; 27(4):595-9. PubMed ID: 2988431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistant rhinoviruses from the nose of experimentally treated volunteers.
    Dearden C; al-Nakib W; Andries K; Woestenborghs R; Tyrrell DA
    Arch Virol; 1989; 109(1-2):71-81. PubMed ID: 2558631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
    Dewindt B; van Eemeren K; Andries K
    Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds.
    Ahmad AL; Tyrrell DA
    Antiviral Res; 1986 Jul; 6(4):241-52. PubMed ID: 3017203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
    Heinz BA; Rueckert RR; Shepard DA; Dutko FJ; McKinlay MA; Fancher M; Rossmann MG; Badger J; Smith TJ
    J Virol; 1989 Jun; 63(6):2476-85. PubMed ID: 2542566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins.
    Mosser AG; Shepard DA; Rueckert RR
    Arch Virol Suppl; 1994; 9():111-9. PubMed ID: 8032243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of flavones and flavans.
    Selway JW
    Prog Clin Biol Res; 1986; 213():521-36. PubMed ID: 3012583
    [No Abstract]   [Full Text] [Related]  

  • 16. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
    Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
    J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.
    Andries K; Dewindt B; Snoeks J; Willebrords R
    Arch Virol; 1989; 106(1-2):51-61. PubMed ID: 2548460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of rhinovirus RNA in nasal epithelial cells by in situ hybridization.
    Bruce C; Chadwick P; al-Nakib W
    J Virol Methods; 1990 Oct; 30(1):115-25. PubMed ID: 1964938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhinovirus colds.
    Phillpotts RJ; Tyrrell DA
    Br Med Bull; 1985 Oct; 41(4):386-90. PubMed ID: 2996687
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837).
    al-Nakib W; Higgins PG; Barrow GI; Tyrrell DA; Andries K; Vanden Bussche G; Taylor N; Janssen PA
    Antimicrob Agents Chemother; 1989 Apr; 33(4):522-5. PubMed ID: 2543283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.